Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$626M |
| 2 |
Warner Bros
WBD
|
+$447M |
| 3 |
Apple
AAPL
|
+$436M |
| 4 |
RTX Corp
RTX
|
+$434M |
| 5 |
Constellation Brands
STZ
|
+$320M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.13B |
| 2 |
Microsoft
MSFT
|
+$502M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$436M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$415M |
| 5 |
EA
Electronic Arts
EA
|
+$388M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.75% |
| 2 | Industrials | 9.36% |
| 3 | Consumer Discretionary | 8.52% |
| 4 | Healthcare | 7.75% |
| 5 | Financials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Ryanair
RYAAY
$29.7B
| $14.9M | 0.02% |
257,083
+166,839
| +185% | +$11M |
|
777
iShares MSCI Emerging Markets ETF
EEM
$31.3B
| $14.8M | 0.02% |
+261,351
| New | +$15.4M |
|
778
Viavi Solutions
VIAV
$9.3B
| $14.8M | 0.02% |
445,079
-9,207
| -2% | -$243K |
|
779
Repligen
RGEN
$10.3B
| $14.8M | 0.02% |
125,469
+10,416
| +9% | +$1.46M |
|
|
SEM
780
DELISTED
Select Medical
SEM
| $14.7M | 0.02% |
904,737
+848,246
| +1,502% | +$13.3M |
|
781
PUT
Booking.com
BKNG
$161B
| $14.7M | 0.02% |
87,500
-82,500
| -49% | -$15.2M |
|
782
Centene
CNC
$32.1B
| $14.7M | 0.02% |
449,966
-314,438
| -41% | -$12.9M |
|
783
Ally Financial
ALLY
$13B
| $14.7M | 0.02% |
375,342
+366,966
| +4,381% | +$15.1M |
|
784
Unity
U
$19.8B
| $14.7M | 0.02% |
670,735
-3,486,536
| -84% | -$96.7M |
|
785
McDonald's
MCD
$190B
| $14.7M | 0.02% |
47,296
-265,062
| -85% | -$84.4M |
|
786
Structure Therapeutics
GPCR
$3.56B
| $14.7M | 0.02% |
304,934
+88,735
| +41% | +$6.07M |
|
787
Infosys
INFY
$48.7B
| $14.6M | 0.02% |
+1,081,011
| New | +$16.9M |
|
788
CALL
Caterpillar
CAT
$373B
| $14.5M | 0.02% |
20,500
-15,000
| -42% | -$10.4M |
|
789
Neurogene
NGNE
$817M
| $14.5M | 0.02% |
718,389
+109,811
| +18% | +$2.13M |
|
790
CALL
UWM Holdings
UWMC
$2.42B
| $14.5M | 0.02% |
+4,000,000
| New | +$18.4M |
|
791
SAB Biotherapeutics
SABS
$347M
| $14.4M | 0.02% |
3,760,439
+3,285,000
| +691% | +$13.1M |
|
792
Roper Technologies
ROP
$40.9B
| $14.4M | 0.02% |
40,610
+38,868
| +2,231% | +$14.3M |
|
793
Prime Medicine
PRME
$673M
| $14.3M | 0.02% |
4,123,365
+999,003
| +32% | +$3.8M |
|
|
SGI
794
Somnigroup International
SGI
$13.5B
| $14.3M | 0.02% |
193,727
-201,866
| -51% | -$17.5M |
|
795
Ares Capital
ARCC
$14.3B
| $14.3M | 0.02% |
793,709
-214,642
| -21% | -$4.16M |
|
796
Verisk Analytics
VRSK
$24.5B
| $14.3M | 0.02% |
75,279
-13,753
| -15% | -$2.79M |
|
797
PUT
PureCycle Technologies
PCT
$1.34B
| $14.3M | 0.02% |
+2,750,000
| New | +$22.9M |
|
798
CALL
Texas Instruments
TXN
$237B
| $14.2M | 0.02% |
73,400
+31,400
| +75% | +$6.36M |
|
799
CALL
Marvell Technology
MRVL
$216B
| $14.2M | 0.02% |
143,600
+16,000
| +13% | +$1.34M |
|
800
Qualcomm
QCOM
$169B
| $14.2M | 0.02% |
110,394
+74,127
| +204% | +$10.8M |
|
Similar funds
Dmitry Balyasny's Q1 2026 Portfolio in Review
As of Q1 2026, Dmitry Balyasny held 3,716 positions worth $77.1B, down 2.1% from $78.8B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Dmitry Balyasny withdrew a net $2.68B in Q1 2026, closing 911 positions and reducing 1,056 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $1.13B position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, down from 12% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in Silicon Laboratories worth $257M.
- Dmitry Balyasny's largest Q1 2026 buy was Silicon Laboratories: 1,233,893 shares worth $257M.
- Dmitry Balyasny added most to Meta Platforms (Facebook) in Q1 2026, an estimated $626M increase.
- Dmitry Balyasny's biggest Q1 2026 reduction was Microsoft, cutting an estimated $502M.
- Dmitry Balyasny fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $1.13B.
- Dmitry Balyasny's ten largest holdings make up 17% of its $77.1B portfolio in Q1 2026.
- Dmitry Balyasny opened 704 new positions and closed 911 in Q1 2026.
- Dmitry Balyasny's portfolio value fell 2.1% quarter-over-quarter to $77.1B.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.